Journals / Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Tıp Dergisi / 2011 / Cilt: 51 - Sayı: 1

Mycoplasma pneumonia in etiology of childhood pneumonia

Çocukluk çağı Pnömoni etyolojisinde Mycoplasma pneumaniae sıklığı

Pages
23–25
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Most of the antibiotics preferred for the empirical treatment of the pneumonia are not effective on the microorganism, Mycoplasma pneumonia, so it leads to decrease the overall success of empirical treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction and aim: The pneumonia is one of the most important causes of mortality in childhood.
📊
Key Findings & Data:Most of the antibiotics preferred for the empirical treatment of the pneumonia are not effective on the microorganism, Mycoplasma pneumonia, so it leads to decrease the overall success of empirical treatment.
💡
Conclusion & Impact:Conclusion: It is important to choose the empirical antibiotic treatment for childhood pneumonia as broad spectrum as that covers one of the important causative agents, mycoplasma pneumonia.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction and aim: The pneumonia is one of the most important causes of mortality in childhood. Since there are not adequate fast and widespread laboratory techniques available for establishing the common microorganisms causing pneumonia, it is not easy to find the causative agent every time. For this reason, antibiotic therapies for pneumonia are started empirically in general. Most of the antibiotics preferred for the empirical treatment of the pneumonia are not effective on the microorganism, Mycoplasma pneumonia, so it leads to decrease the overall success of empirical treatment. Aim of our study is to find out the incidence of Mycoplasma pneumonia and to increase the overall efficacy of empirical antibiotic treatment of pneumonia by improving the choice of appropriate agent. Methods: Serum specific IgM antibody against Mycoplasma pneumonia is investigated in the specimens of patients with pneumonia. Result: Mycoplasma pneumonia was the causative organism in 18.6 % of the patients with pneumonia. Conclusion: It is important to choose the empirical antibiotic treatment for childhood pneumonia as broad spectrum as that covers one of the important causative agents, mycoplasma pneumonia.

Özet

GİRİŞ VE AMAÇ Giriş ve amaç: Pnömoni çocukluk çağının en önemli mortalite sebeplerinden biridir. Pnömonide etyolojik ajanın saptanması, sık rastlanılan etkenlere yönelik kesin ve hızlı tanı yöntemlerinin olmaması nedeniyle zordur. Bu nedenle pnömonilerde genellikle ampirik antibiyotik tedavisi başlanmaktadı r. Sıklıkla seçilen antibiyotiklerin Mycoplasma pneumoniae tedavisinde etkili olamaması tedavi başarısını azaltmaktadır. Bu çalışma sık karşılaşı lan pnömoni etkenlerinden biri olan Mycoplasma pneumoniae (MP) sıklığını araştırarak daha isabetli tedavi seçimine yardımcı olmayı amaçladı k. Yöntem: Pnömoni tanısı alan hastaların kan örneklerinde Mycoplasma pneumoniae‘ya karşı gelişen serum spesifik İmmunglobulin M indirekt immünofloresan yöntemiyle araştırıldı. Sonuç: Pnömoni tanısı konan hastaların % 18,6’sında Mycoplasma pneumoniae hastalık etkeni saptandı. Tartışma: Pnömoni tanısı konan çocuk yaş grubu olgularda ampirik antibiyotik tedavisi başlanması nda seçilecek ajanın M. pneumoniae’yı da kapsayacak şekilde etkin bir spektruma sahip olması na dikkat edilmelidir.

🔖

Cite This Article

ERDOĞAN, F., ÇİFTÇİ, M. (2022). Mycoplasma pneumonia in etiology of childhood pneumonia. Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 51 - Sayı: 1, 23–25. https://ajindex.com/articles/535441

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. 1 Barson WJ. Treatment of community aquired and nosocomial pneumonia in children. Version 12,3. http:// www.uptodate.com (accessed August, 2004). 2 Ranganathan SC, Sonnappa S. Pneumonia and other respiratory infections. Pediatr Clin N Am 2009
  2. Rudan I, Tomaskovic L, Boschi-Pinto C, Campbell H. Global estimate of the incidence of clinical pneumonia among children under five years of age. Bull World Health Organ 2004
  3. 8 2: 895-903 4. Klein JO. Bacterial pneumonias.Feigin RD, Cherry JD, Demler GJ, Kaplan Sl (ed). Textbook of Pediatric Infectious Diseases, 5. basım. Philadelphia: Saunders, 2004: 299- 310. basım. Philadelphia: Saunders, 2004: 299-310. 5. Kocabaş E, Yalçın E, Akın L ve ark. Çocukluk Ça¤ında Toplum Kökenli Pnömoni Tanı ve Tedavi Rehberi. Erişkin ve Çocuklarda Toplum Kökenli Pnömoniler ve Akut Bronşiolit Tanı ve Tedavi Rehberleri. Toraks Dergisi 2002
  4. 3 (Ek-3):19-30. 6. Ostapchuk M, Roberts D, Haddy R. Community-Acquired Pneumonia in Infants and Children. Am Fam Physician 2004
  5. British Thoracic Society. British Thoracic Society guidelines for the management of community acquired pneumonia in childhood. Thorax 2002
  6. 57(Suppl I): i1-24. 8 Korppi M. Community-Aquired Pneumonia in Children. Issues in Optimizing Antibacterial Treatment. Pediatr Drugs 2003
  7. 832 9. Ramsey BW, Marcause EK, Foy HM et al. Use of bacterial antigen detection in the diagnosisof pediatric lower respiratory tractinfections. Pediatrics 1986
  8. 78(1): 1-9. 10 Woodhead MA, Macfarine JT, McCracken JS, et al. Prospective study of the etiology and outcome of pneumonia in the community. Lancet 1987
  9. 11 World Health Organization. The management of acute respiratory infections in children. Geneva: WHO, 1995.